V5
路漫漫 声望 155
生物医学
Treatment of renal cell carcinoma: Current status and future directions
作者:Pedro C. Barata MD, MSc, Brian I. Rini MD
摘要:Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents. Multiple agents—including molecules against vascular endothelial growth factor, platelet-derived growth factor, and related receptors; inhibitors of other targets, such as the mammalian target of rapamycin and the MET and AXL tyrosine-protein kinase receptors; and an immune-checkpoint inhibitor—have been approved based on significant activity in patients with advanced RCC. Despite these advances, important questions remain regarding biomarkers of efficacy, patient selection, and the optimal combination and sequencing of agents. The purpose of this review is to summarize present management and future directions in the treatment of metastatic RCC. CA Cancer J Clin 2017;67:507-524. © 2017 American Cancer Society.
关键词:renal cell carcinoma,Treatment
论文方向:
发表期刊:CA-A CANCER JOURNAL FOR CLINICIANS
数字识别码:DOI:10.3322 / caac.21411
是否作者本人:

版权及免责声明:

本网站所有论文文件均系用户自行上传或提供,本网站对其内容准确性及合法性概不负责,亦不承担任何法律责任。论文版权归原作者及原出处所有。

如您发现网站其他用户上传的论文有侵犯您的姓名权、隐私权、著作权或其他合法权益现象的,请及时与本网站联系并附加相关权利证明文件,以便本网站及时作出处理,维护您的合法权益。

本网站拥有对此声明的最终解释权。

全部评论 ( 0 )

发评论
9.3/10分

1人评分